上海萊士(002252.SZ):擬終止萊士南方生物製品生產基地項目
格隆匯3月15日丨上海萊士(002252.SZ)公佈,公司於2022年3月15日以通訊方式召開了第五屆董事會第十二次(臨時)會議,審議通過了《關於終止萊士南方生物製品生產基地項目的議案》等,同意終止萊士南方生物項目,並授權鄭州萊士血液製品有限公司(“鄭州萊士”)董事長周道平或公司指定的授權代表人簽署與本次終止項目涉及的相關文件,辦理終止事項的相應手續。
基於公司戰略發展需要,公司於2019年2月同意鄭州萊士在湖南省長沙市設立萊士南方生物。鄭州萊士組建了專業的團隊具體落實各項工作,先後取得了湖南省部分縣(市)衞生部門同意設置單採血漿站的縣級批文,並積極與相關方進行了反覆磋商和密切配合,為投資事項的具體落地和實施做了大量基礎和有效的工作,極力推動上述漿站的省級主管部門審批工作。截止目前,上述漿站項目尚未獲得省級主管部門的審批,生產基地所需的土地未完成招拍掛流程,生產基地建設未正式實施。
萊士南方生物項目兼具漿源開發及投資新建後進行異地搬遷的特點,需要協調的資源及各級行政部門較多,項目各環節審批較為複雜,項目投資週期跨度較長,行業政策、經濟形勢、市場環境等變化均對項目的實施和進度產生一定的影響,幾經努力,項目至今仍未能取得實質性進展,如繼續實施,仍存在較多不確定因素。
綜合各方面因素,經審慎研究,公司決定終止萊士南方生物項目,進一步聚焦和強化日常經營管理工作,集中優勢資源全力推進新漿站的開發和審批工作。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.